Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 17/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 17/20 | 1.00 |
| ▸ | RELA | Q04206 | 17/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CLPX | O76031 | 1/20 | 0.81 |
| ▸ | VCP | P55072 | 1/20 | 0.81 |
| ▸ | RORA | P35398 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Withaferin A SCHEMBL12309163 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL29398581 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL30782710 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL12309137 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL17807718 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL24075907 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL11950371 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL157208 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL18372363 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| SCHEMBL12309145 | 0.94 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199634-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. | 2024-05-09 | — | — | US | disclosed |
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11963950-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240123016-A1 | WITHANOLIDE-ENRICHED COMPOSITIONS AND METHODS OF USE THEREOF | CAVALERI FRANCO (CA) | 2024-04-18 | — | — | US | disclosed |
| US-20240082339-A1 | WITHANOLIDE-ENRICHED COMPOSITIONS & METHODS OF USE THEREOF | CAVALERI FRANCO (CA) | 2024-03-14 | — | — | US | disclosed |
| WO-2024020534-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4308573-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10144734-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-10137124-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-10112942-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | MALT1, LITAF, IL2 | NFKB1 543/4885NFKB2 990/4885RELA 1328/4885 |
| US-20240123016-A1 | WITHANOLIDE-ENRICHED COMPOSITIONS AND METHODS OF USE THEREOF | EBP, NFE2L2, HMOX1 | NFKB1 206/4885NFKB2 51/4885RELA 179/4885 |
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | NFKB1 2544/4885NFKB2 3317/4885RELA 4327/4885 |
| US-11963950-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | RET, ALK, BRAF | NFKB1 2001/4885NFKB2 2416/4885RELA 4096/4885 |
| US-10144734-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | NFKB1 1862/4885NFKB2 2573/4885RELA 3889/4885 |
| US-10112942-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | NFKB1 2544/4885NFKB2 3317/4885RELA 4327/4885 |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | RET, BRAF, ROR1 | NFKB1 2460/4885NFKB2 3553/4885RELA 4501/4885 |
| US-20240199634-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | PLK1, DCK, CSNK1A1 | NFKB1 1285/4885NFKB2 1329/4885RELA 2496/4885 |
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | RET, ROR1, FRK | NFKB1 2995/4885NFKB2 3039/4885RELA 3399/4885 |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | NFKB1 2544/4885NFKB2 3317/4885RELA 4327/4885 |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | NFKB1 1862/4885NFKB2 2573/4885RELA 3889/4885 |
| US-20240082339-A1 | WITHANOLIDE-ENRICHED COMPOSITIONS & METHODS OF USE THEREOF | EBP, HMOX1, KEAP1 | NFKB1 18/4885NFKB2 4/4885RELA 123/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | NFKB1 1862/4885NFKB2 2573/4885RELA 3889/4885 |
| US-10137124-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | NFKB1 2544/4885NFKB2 3317/4885RELA 4327/4885 |
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | NFKB1 2544/4885NFKB2 3317/4885RELA 4327/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | NFKB1 1862/4885NFKB2 2573/4885RELA 3889/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | NFKB1 2544/4885NFKB2 3317/4885RELA 4327/4885 |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | MALT1, FKBP1B, FKBP1A | NFKB1 475/4885NFKB2 745/4885RELA 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.